Articles from Vigil Neuroscience, Inc.

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · January 30, 2025

- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · January 23, 2025

– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 –
By Vigil Neuroscience, Inc. · Via GlobeNewswire · January 8, 2025

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will be presenting at the following conferences in November:
By Vigil Neuroscience, Inc. · Via GlobeNewswire · November 12, 2024

- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · November 7, 2024

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 11, 2024, at 10:30 a.m. ET.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · November 5, 2024

WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial of VG-3927. The FDA’s decision was based on a complete response submitted by the Company.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · September 17, 2024

WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · September 16, 2024

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · August 29, 2024

- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · August 13, 2024

- CSF1R pathogenic and likely pathogenic variants reported to have an approximate prevalence of 281 per 1 million -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · August 1, 2024

- First presentation of clinical data on sTREM2 from SAD cohorts in ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers demonstrate proof-of-pharmacology -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · July 30, 2024

- Safety, tolerability, pharmacokinetic and pharmacodynamic profile of VG-3927 supports continued development as potential once-daily oral therapy for Alzheimer’s disease (AD) -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · July 24, 2024

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations highlighting its oral small molecule VG-3927 at the 2024 Alzheimer's Association International Conference (AAIC) taking place on July 28-August 1, 2024 in Philadelphia, Pennsylvania and virtually.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · July 18, 2024

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today an update following a Type C Meeting with the U.S. Food and Drug Administration (FDA) to its clinical development strategy for its IGNITE clinical trial evaluating iluzanebart in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
By Vigil Neuroscience, Inc. · Via GlobeNewswire · July 18, 2024

- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock-
By Vigil Neuroscience, Inc. · Via GlobeNewswire · June 27, 2024

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management’s participation at two upcoming investor conferences.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · May 30, 2024

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · May 8, 2024

– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 –
By Vigil Neuroscience, Inc. · Via GlobeNewswire · May 7, 2024

- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · April 17, 2024

– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP –
By Vigil Neuroscience, Inc. · Via GlobeNewswire · March 26, 2024

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer. Dr. Kaufmann succeeds Christopher J. Silber, M.D.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · March 20, 2024

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · March 13, 2024

WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President will participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Tuesday, March 19th at 3:30 p.m. E.T.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · March 12, 2024

Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to favorably tune microglia activation
By Vigil Neuroscience, Inc. · Via GlobeNewswire · March 6, 2024

Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients’ barriers to genetic testing
By Vigil Neuroscience, Inc. · Via GlobeNewswire · February 29, 2024

WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, at 1:30 p.m. E.T.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · February 7, 2024

- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · January 3, 2024

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Tuesday, November 28, at 3:50 p.m. E.T.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · November 22, 2023

- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · November 16, 2023

– Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter –
By Vigil Neuroscience, Inc. · Via GlobeNewswire · November 7, 2023

WATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Company has dosed its first participant in a Phase 1 clinical trial in healthy volunteers evaluating VG-3927, the first and only small molecule TREM2 agonist in the clinic for the potential treatment of Alzheimer’s disease (AD).
By Vigil Neuroscience, Inc. · Via GlobeNewswire · October 17, 2023

WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 1:30 p.m. ET.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · October 5, 2023

WATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the Company’s application for orphan drug designation for VGL101 for the treatment of CSF1R-related leukoencephalopathy, which includes adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). The Company is currently evaluating VGL101 in a Phase 2 proof-of-concept trial in patients with ALSP. VGL101 was previously granted orphan drug designation by the U.S. Food and Drug Administration for ALSP in July 2022.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · September 26, 2023

- Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · September 11, 2023

- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · September 8, 2023

WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of the management team will participate in a fireside chat at the 2023 Morgan Stanley Global Healthcare Conference in New York City on Monday, September 11, 2023, at 9:20 a.m. ET.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · September 8, 2023

- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · August 8, 2023

WATERTOWN, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Christopher J. Silber, M.D. as Chief Medical Officer. Dr. Silber brings over 30 years of biopharmaceutical industry experience and a track record of clinical and regulatory success developing novel therapeutics in neuroscience.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · August 7, 2023

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of the management team will participate in a fireside chat at the 2023 Jefferies Global Healthcare Conference in New York City on Thursday, June 8, 2023, at 9:00 a.m. ET.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · June 1, 2023

- Partial clinical hold lifted by FDA on VGL101 -
By Vigil Neuroscience, Inc. · Via GlobeNewswire · May 10, 2023

WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced it appointed Samantha Budd Haeberlein, Ph.D. to its Board of Directors.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · May 9, 2023

– New genetic testing initiative designed to enable improved patient diagnosis of ALSP, a devastating, rare genetic neurodegenerative disease –
By Vigil Neuroscience, Inc. · Via GlobeNewswire · May 8, 2023

Company remains on track to report interim data from Phase 2 trial in the second half of 2023
By Vigil Neuroscience, Inc. · Via GlobeNewswire · March 30, 2023

WATERTOWN, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2023 CNS Days virtual conference on Wednesday, March 29, 2023, at 12:00 p.m. ET.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · March 22, 2023

– Dosed first patient in IGNITE Phase 2 clinical trial to evaluate VGL101 in patients with ALSP –
By Vigil Neuroscience, Inc. · Via GlobeNewswire · March 21, 2023

WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced multiple oral and poster presentations on adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) at the 2023 American Academy of Neurology (AAN) Annual Meeting taking place on April 22-27, 2023, in Boston, MA and virtually.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · March 2, 2023

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 8:15 a.m. PT / 11:15 a.m. ET.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · January 3, 2023

– Dr. David Gray brings nearly 20 years of preclinical and clinical research and drug development expertise in neurological diseases –
By Vigil Neuroscience, Inc. · Via GlobeNewswire · December 15, 2022

First-ever interventional trial for patients with ALSP, a rare and rapidly progressing neurological disease with significant unmet medical need
By Vigil Neuroscience, Inc. · Via GlobeNewswire · December 14, 2022

CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Company will host an adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) Key Opinion Leader (KOL) event for the investment community in New York City on Tuesday, December 6, 2022, from 8:30 a.m. – 11:30 a.m. ET.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · November 28, 2022

–Announced interim topline data from Phase 1 trial of VGL101 in healthy volunteers–
By Vigil Neuroscience, Inc. · Via GlobeNewswire · November 10, 2022

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at three upcoming investor conferences. Details are as follows:
By Vigil Neuroscience, Inc. · Via GlobeNewswire · November 7, 2022

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced interim topline results from its ongoing Phase 1 clinical trial of VGL101, its lead product candidate, in healthy volunteers. These interim data support the initiation of a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) with a 20 mg/kg dose.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · November 2, 2022

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VGL101 for the treatment of patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). VGL101, Vigil’s lead product candidate, is a monoclonal antibody TREM2 agonist currently being evaluated in a Phase 1 trial in healthy volunteers.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · November 1, 2022

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Suzanne Bruhn, Ph.D. to its Board of Directors.
By Vigil Neuroscience, Inc. · Via GlobeNewswire · July 28, 2022